Cargando…
Possible Novel Therapy for Malignant Gliomas with Secretable Trimeric TRAIL
Malignant gliomas are the most common primary brain tumors. Despite intensive clinical investigation and many novel therapeutic approaches, average survival for the patients with malignant gliomas is only about 1 year. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) has shown potent...
Autores principales: | Jeong, Moonsup, Kwon, Yong-Sam, Park, Soon-Hye, Kim, Chae-Young, Jeun, Sin-Soo, Song, Kang-Won, Ko, Yong, Robbins, Paul D., Billiar, Timothy R., Kim, Byong-Moon, Seol, Dai-Wu |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2641005/ https://www.ncbi.nlm.nih.gov/pubmed/19229339 http://dx.doi.org/10.1371/journal.pone.0004545 |
Ejemplares similares
-
Combination treatment with VPA and MSCs-TRAIL could increase anti-tumor effects against intracranial glioma
por: Park, Soon A., et al.
Publicado: (2021) -
A hypoxia- and telomerase-responsive oncolytic adenovirus expressing secretable trimeric TRAIL triggers tumour-specific apoptosis and promotes viral dispersion in TRAIL-resistant glioblastoma
por: Oh, Eonju, et al.
Publicado: (2018) -
Combination Therapy for Gliomas Using Temozolomide and Interferon-Beta Secreting Human Bone Marrow Derived Mesenchymal Stem Cells
por: Park, Jae-Hyun, et al.
Publicado: (2015) -
Associations of General and Abdominal Obesity with the Risk of Glioma Development
por: Ahn, Stephen, et al.
Publicado: (2021) -
Temozolomide Chemotherapy in Patients with Recurrent Malignant Gliomas
por: Yang, Seung-Ho, et al.
Publicado: (2006)